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Abstract
The asthma syndrome has many manifestations, termed phenotypes that arise by specific 
cellular and molecular mechanisms termed endotypes. Understanding helps clinicians make 
rational therapeutic decisions. Omalizumab has been widely used in clinical practice in 
Europe and America for over a decade as an add-on therapy to treat patients who have severe 
asthma. These real-world clinical effectiveness studies have confirmed the benefits, cost-effec-
tiveness, and clinical utility. The purpose of this review is to present the effects of anti-IgE 
treatment in severe non-atopic asthma and in asthma-COPD overlap syndrome (ACOS). This 
study describes that the use of omalizumab therapy reduces IgE expression and IgE sensiti-
zation of target cells within the bronchial mucosa while exerting a favorable effect on lung 
function in the short term, as assessed by changes in forced expiratory volume in 1 s (FEV1).
Keywords: omalizumab, non-atopic asthma, ACOS, phenotypes, severe asthma
1. Introduction
Severe asthma is a highly heterogeneous and burdensome disease that requires individualized 
assessment and management. The exact prevalence of severe asthma is unknown, but it has 
been reported to affect 5–10% of the population with asthma. Although some patients have 
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asthma that remain poorly controlled despite high doses of inhaled corticosteroid (ICS) with 
or without additional controlled therapies including long-acting muscarinic antagonists and 
theophylline. Uncontrolled severe asthma significantly affects the activities of daily living, mor-
bidity, mortality, quality of life (QOL), and health care use. Indeed, severe asthma accounts for 
approximately 50% of all asthma-related health care costs, direct (physician visits, hospitaliza-
tions, intensive care, and medications) and indirect (missed school days and work absenteeism). 
Categorically, uncontrolled and severe asthma remains a health and economic burden in many 
countries. Nowadays, we have a targeted therapy to control the burden disease with excellent 
results. In this chapter, we discuss the benefits of the use of omalizumab (OmAb) in patients 
with non-atopic and asthma COPD overlap syndrome (ACOS) phenotype. [1] (Figure 1).
2. Non-atopic asthma and IgE
The concept of asthma in our practice is a complex disease. Atopy is a familiar knowledge but the sig-
nificance of non-atopic or non-allergic is a new definition to treat the patients with moderate-to-severe 
asthma. The presence of negative prick test and presence or not of eosinophilia is an opportunity to 
use biologics to improve symptoms and quality of life [2–3]. The possible association of serum IgE 
levels with asthma, irrespective of specific allergic sensitization has long been investigated. Burrows 
et al. revealed that IgE-mediated mechanisms might play a role even in non-atopic asthmatics with 
no detectable allergen-specific IgE. Some studies have shown that up to 25% of adult asthmatics are 
non-allergic. We proposed to treat the patients according to different types [4–6] (Figure 1).
A minority of asthmatic individuals are not however demonstrably atopic by conventional 
criteria, which has led to the suggestion that asthma maybe divided clinically into atopic and 
non-atopic. Recently, there have been major advances in our understanding of the molecular 
mechanisms of non-atopic. Indeed, the mechanisms of this variant of asthma in which allergens 
have no obvious role in driving inflammatory process in the airways remain uncertain. This type 
of research will certainly point towards new types of mechanisms, which will allow a more per-
sonalized way to treat asthma [7].
3. Local and peripheral IgE synthesis in severe asthma
Non-atopic asthma patients are typically a late-onset condition, more common in females, 
and it tends to be more severe than atopic form, requiring higher doses of corticosteroids for 
Figure 1. Definitions.
Asthma Diagnosis and Management - Approach Based on Phenotype and Endotype186
adequate control. It often starts following a severe upper or lower respiratory tract infection 
or during pregnancy, but it also indicates that environmental factors may be more important 
in the causation of non-atopic asthma. The presence of increased local synthesis of IgE also 
in non-atopic asthmatics has been demonstrated in more recent studies. Ying et al. showed 
local expression of epsilon heavy chain of IgE in the bronchial mucosa in atopic and non-
atopic asthmatics. Mouthuy et al. confirmed that local IgE production occurs in the bronchial 
mucosa in atopic asthma and showed for the first time, that this part of IgE is directed towards 
house dust mite allergens. [8–10].
We described in 2015, the presence of non-atopic phenotype in a population of 10 asthmatics 
in a cohort with omalizumab treatment in University Hospital of Puebla, Mexico. Since the 
identification of IgE as a major stimulus in the inflammation cascade, the development of 
agents to target IgE has thrived. [11] (Table 1).
4. Anti-IgE drug omalizumab: mechanism of action
Omalizumab (OmAb) is a recombinant humanized monoclonal antibody that was designed 
to bind to IgE on the Fc (constant fragment) portion, C epsilon 3 locus, in the same domain 
where IgE is bound to FcRI. This drug was synthesized with the aim of sequestering free 
IgE and reducing allergic inflammation. This drug is administered subcutaneously and is 
absorbed slowly. The peak of serum concentration is reached after 7−8 days and it is elimi-
nated via reticuloendothelial system having a half-life of around 26 days. It has been accepted 
for a long time that OmAb acts on the free IgE and abolish the binding of IgE to FcRI or FcRII, 
CD23 cells, B-cells, dendritic cells (DC), eosinophils (Eo), and monocytes. In several real-life 
studies, the use of OmAb has been associated with an absence of exacerbations and improve-
ment in the quality of life, which is reflected in reduced hospital admissions and emergency 
visits but not in pulmonary function. The standard duration of treatment with OmAb has not 
been established to date. A follow-up study showed that after 6 years of OmAb treatment, 
Cell types of epithelial components Atopic asthma Non-atopic asthma
Ciliated columnar Damage ++ Damage +
Desmosomes Breakdown ++ Breakdown +
Globlet cells Hyperplasia (+) Hyperplasia (−)
Basal cells Damage + Damage +
Basement membrane Thickening ++ Thickening +
Eosinophils Infiltration +++ Inflitration +++
Neutrophils Inflitration + Inflitration ++
Mast cells Inflitration ++ Infiltration +
Lymphocytes Infiltration +++ Infiltration ++
Macrophages Infiltration + Infiltration ++
Table 1. Comparison of bronchial epithelial components in atopic and non-atopic asthma.
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most patients have mild and stable asthma in the ensuing 3 years after treatment discontinu-
ation, it has been suggested that the persistence of the effects of OmAb may be due to its 
ability to curtail airway remodeling in patients with asthma. In fact, it has been found that 
OmAb significantly decreased the airway wall area. After 1 year of omalizumab treatment, a 
significant mean reduction in eosinophilic infiltration was recorded as well as a reduction in 
the reticular base membrane in bronchial biopsies from patients with severe persistent aller-
gic asthma was observed. These findings indicate that OmAb may modify the course of the 
disease due to their possible influence curtailing airway remodeling [12].
5. Anti-Immunoglobulin E in non-atopic asthma with omalizumab
In an attempt to elucidate the drug’s mechanism of action, OmAb regulated FcRI expression 
negatively on basophils and plasmacytoid dendritic cells and increased forced expiratory vol-
ume in the first minute (FEV1) compared with baseline after 16 weeks in patients with severe 
non-atopic asthma demonstrated the possible role of IgE in non-atopic asthmatics [12–14]. The 
concept of Omalizumab treatment in non-atopic asthma is a new provocative idea and initially, 
some reports cases and data from severe asthma registries gave food for thought and discussion 
[15–16].
We concluded the functional role of local polyclonal IgE in airway mucosal tissue also in view 
of the finding of eosinophilic inflammation in nasal polyps with increased local tissue IgE lev-
els independently of the allergic status of the patients. We presented the same case to Mexican 
female patient in University hospital of Puebla and showed the benefits of omalizumab in 
symptoms, QOL, and acute exacerbations, not in pulmonary function [13, 17].
6. Effects of omalizumab in non-atopic asthma patients
Eosinophilic asthma has been considered a phenotype of severe asthma. Allergic asthma can 
present with normal or increased numbers of eosinophils. The guidelines generally do not 
distinguish between the pathways responsible for the eosinophilia (atopic or non-atopic). 
Omalizumab can decrease the number of eosinophils in sputum on the bronchial mucosa 
and to a lesser extent in peripheral blood, in some cases, omalizumab fails to improve allergic 
asthma, this in probably due to the fact that the predominant physiopathological dysregula-
tion comer initially from adaptive immunity, probably as a consequence of the highly intense 
activity of the allergic cascade. [18–19].
As a result of all these different modes of action, omalizumab has also been shown to interfere in 
certain stages of the remodeling process. [20–23]. Kutlu et al. described a case with 34 years old 
male patient the use of omalizumab with negative skin prick test and IgE in 203 U/L, they use 
omalizumab a dose of 225 mg every 2 weeks and after 6 months the patient was scored as 7 to 25 
points at the asthma control test before the treatment of anti-IgE. We described and showed the 
improvement or non-atopic patients with omalizumab and started with 150 mg of omalizumab 
in our asthma Clinic in Puebla and increased the doses with excellent results [20–24].
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7. Asthma-COPD overlap syndrome
Asthma and chronic obstructive pulmonary disease (COPD) are two common respira-
tory disorders which are associated with chronic inflammation or the airways. In text 
books, the two are described as distinct disorders, however, there is increasing awareness 
that in clinical practice many patients may have features of both. ACOS is a subset of 
patients with persistent airflow limitation who have clinical features of both asthma and 
COPD. (25).
Patients with ACOS have largely excluded from studies and hence information on their epi-
demiology, pathogenesis and treatment is sparse, we described in a COPD cohort from pneu-
mology department in our asthma COPD clinic prevalence was 10 and 25% in asthma cohort. 
Another study described in COPD cohort has 15% of them fulfilling criteria for ACOS. Another 
study done in asthmatics who were smokers, found that 27% of them had ACOS. However, 
another study done showed that only 7% of asthma/COPD patients had ACOS. This wide 
variation can be partly attributed to the difference in the criteria used to diagnose ACOS in 
the above studies. The lack of consensus on a definition for ACOS has led to the wide range 
in prevalence varying between 11 and 56% among COPD, 13 and 61% among asthma, and 2% 
among the general population [25–30] (Tables 2 and 3).
Major criteria Minor criteria
1. Persistent airflow limitation (post bronchodilator FEV1/
FVC ratio < 0.70 of lower limit of normal) in individuals 
aged 40 years or older.
1. Documented history of atopy or allergic rhinitis.
2. At least 10 pack years of tobacco smoking or equivalent 
exposure to indoor of outdoor pollutants (biomass).
2. Bronchodilator response (BDR) using 400 mcg of 
albuterol/salbutamol >200 ml and 12% from baseline 
values on 2 or more visits.
3. Documented history of asthma before the age of 40 years 
or BDR >400 ml in forced expiratory volume in 1 s (FEV1).
FVC = Forced vital capacity
3. Peripheral blood eosinophil count >300 cells/μL.
The criteria for diagnosis of ACOS consist of 3 major and 3 minor criteria. To diagnose ACOS, it is necessary to have 3 
major criteria and at least 1 minor criteria.
Table 2. Expert consensus major and minor criteria for ACOS.
Major criteria Minor criteria
1. Very positive bronchodilator test (increase in 
FEV1 > 15% and >400 ml
1. High Level of total IgE
2. Sputum eosinophils 2. Personal history of atopy
3. History of asthma 3. Positive bronchodilator test on at least 2 occasions (increase of 
FEV1 > 12% and 200 ml).
For diagnosis at least 2 major criteria of 1 major criteria with 2 minor criteria.
Table 3. SEPAR criteria for mixed COPD/asthma phenotype in COPD.
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8. Recently use of biologicals for ACOS
In the past decade, interest in the clinical characteristics, importance and consequences for 
patients with overlapping features of asthma and COPD has been renewed. In their purest 
forms, asthma and COPD are distinct and readily recognizable clinical entities. Furthermore, 
guidelines for treatment of asthma and COPD are well established and evidence-based.
The unknowns continue to mount for patients in this overlap syndrome group who are 
unresponsive to existing treatments but continue to be symptomatic and at increased risk 
for exacerbations. The absence of treatment guidelines becomes particularly problematic 
when the use of biological is being considered. Experience with biological is most exten-
sive with asthma, but studies of asthma treatments often exclude subjects with a history 
of smoking. Furthermore, in studies in COPD, a history of asthma is usually and exclu-
sion criterion. Therefore, well recognized evidence-based guidance is largely absent as 
to what might be the best therapeutic approach, what patient characteristics are most 
predictive in selecting a specific next treatment of what outcomes are most likely to reflect 
treatment responsiveness. As many patients with asthma-COPD overlap syndrome might 
not achieve disease control with existing treatments, the consideration for and selection 
of a biological agent is an important unmet clinical need, both for the clinician and the 
affected patient [31].
Chest, Steven Maltby and colleagues at the University of Newcastle in Australia began to 
address this largely open question. What are the effects of omalizumab in this patient cohort? 
The Australian Xolair Registry was used to evaluate the real world use of omalizumab for 
severe uncontrolled allergic asthma. A total of 177 participants were evaluated and 17 of 
these had a doctor diagnosis of COPD. Omalizumab was found to be equivalently effective 
in patients with severe allergic asthma and a physician diagnosis of COPD, as well as severe 
asthma without COPD. In severe asthma and COPD, the asthma control questionnaire (ACQ) 
improved from 3.68 to 1.69 with the addition of omalizumab [31].
Initial studies have shown that omalizumab may be useful in patients with ACOS. It has 
been shown to improve symptoms, reduce exacerbations and hospitalization, and improve 
lung function parameters and reduced steroid requirement in these patients. However, larger 
randomized trial is required to further validate this observation. We presented the effects of 
omalizumab in ACOS patients with an excellent result in a group of 5 patients of the asthma 
COPD cohort clinic in University hospital of Puebla and showed improved lung function and 
symptoms [31–33].
Nayci et al. published the effectiveness of omalizumab treatment in asthma-COPD overlap 
syndrome in 2016 and described a clinical reduction in exacerbations and steroid requirement 
and improved symptoms and pulmonary function parameters in 6 patients. Dammert et al. 
published the use of Omalizumab in patients with COPD and atopic phenotypes in 7 cohort 
patients with positive allergy test and showed that omalizumab reduced the number of exac-
erbations, hospitalizations, and improved symptoms [34–35].
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9. Conclusion
To conclude, there is now evidence suggesting that omalizumab improves patients with 
severe non-atopic asthma and ACOS. Therefore, it is important to review each patient meticu-
lously and regularly and provide personalized and targeted treatment. In the case of using 
omalizumab to treat non atopic severe asthma, the evidence is conclusive in these pheno-
types. In the era of personalized and targeted medicine, it is important to fully characterize 
our patients and prescribe treatment that aims at treating the particular patient to consider the 
cost-effectiveness. In this chapter, we described that omalizumab is efficient and safe to treat 
and improves and increases the quality of life.
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